CorVista Health presents heart test data at ACC.25

CorVista Health has announced that it will present new research at the American College of Cardiology's Annual Scientific Session (ACC.25) in Chicago. The focus will be on its non-invasive test for measuring pulmonary capillary wedge pressure (PCWP). This pressure is an important indicator of heart failure, particularly heart failure with preserved ejection fraction (HFpEF). The presentation will take place on March 30, 2025. Dr. Charles Bridges, the Chief Scientific Officer of CorVista Health, will lead the poster presentation titled "Point-of-Care Testing for Pulmonary Capillary Wedge Pressure Elevation Using Machine Learning on Non-Invasive Signals." The presentation will run from 12:00 p.m. to 1:00 p.m. ET at the South Hall. CorVista Health will also showcase its CorVista System at Booth #FH8 in the Future Hub. This digital health solution can detect various heart conditions through a single, quick test that takes under 30 minutes. The system uses machine learning to analyze heart signals. The CorVista System gained U.S. Food and Drug Administration (FDA) clearance for coronary artery disease in September 2023 and for pulmonary hypertension in April 2024. It aims to improve cardiovascular care by providing faster and more accessible testing for patients, especially those underserved by traditional healthcare systems.